
Multiple Sclerosis Research Findings Top SPT Week in Review
Top news of the week from Specialty Pharmacy Times.
5. Investigational HIV Therapy Further Demonstrates Efficacy in Phase 3 Trial
Study evaluates doravirine once daily compared with ritonavir-boosted darunavir, each taken in combination with other antiretroviral agents. 
4. FDA Approves Extended-Release Injectable Suspension for Schizophrenia
Officials with the FDA have approved risperidone (Perseris, Indivior) for extended-release injectable suspension for the treatment of schizophrenia in adults. 
3. FDA Grants Fast Track Designation to Hepatitis B Drug
The FDA recently granted Fast Track designation to Assembly Biosciences, Inc’s novel treatment for patients with chronic hepatitis B virus (HBV) infection. 
2. Use of Truvada for HIV Prevention Associated with Decline in New US Diagnoses
Nationwide analysis of Truvada for pre-exposure prophylaxis use finds uptake associated with significant decrease in new HIV infections. 
1. Research Sheds Light on New Drug Targets for Regenerative MS Therapies
Study finds that several multiple sclerosis drug candidates inhibit the same enzyme to stimulate myelin regeneration. 
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.














































































































































































































